JAK2 and myeloproliferative neoplasm: This provides additional mechanistic evidence that targeting the MEK/ERK pathway may enhance the efficacy of ruxolitinib by antagonizing inflammatory cytokine expression, as shown by Stivala et al. [65] who used MPN mouse models to show that combining MEK and JAK2 inhibition provides greater suppression of ERK target genes and cytokine expression.